Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli

Vaccine

Volumn 24, Issue 40-41, 2006, Pages 6405-6413

  Sloat, Brian R ^a   Cui, Zhengrong ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Complement mediated bacterial killing; dsRNA; Mucosal immunization; Toxin neutralization

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; CARRIER PROTEIN; DOUBLE STRANDED RNA; IMMUNOLOGICAL ADJUVANT; POLYGLUTAMIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACILLUS ANTHRACIS; BACTERICIDAL ACTIVITY; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX VACCINES; ANTIBODIES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BRONCHOALVEOLAR LAVAGE; CATTLE; CELL PROLIFERATION; CELL SEPARATION; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; NOSE; POLYGLUTAMIC ACID; POLYNUCLEOTIDES; SERUM ALBUMIN, BOVINE; SPLEEN;

EID: 33748329494     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.002     Document Type: Article

References (43)

1. 2 and a trans-acting element activate transcription from one of two promoters. J Bacteriol 176 3 (1994) 586-595
2. Dixon T.C., Meselson M., Guillemin J., and Hanna P.C. Anthrax. N Engl J Med 341 11 (1999) 815-826
3. Inglesby T.V., O'Toole T., Henderson D.A., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 17 (2002) 2236-2252
4. Puziss M., Manning L.C., Lynch J.W., Barclaye, Abelow I., and Wright G.G. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl Microbiol 11 (1963) 330-334
5. Bradley K.A., Mogridge J., Mourez M., Collier R.J., and Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 414 6860 (2001) 225-229
6. Ascenzi P., Visca P., Ippolito G., Spallarossa A., Bolognesi M., and Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett 531 3 (2002) 384-388
7. Brossier F., Levy M., and Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70 2 (2002) 661-664
8. Wang J.Y., and Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4 1 (2005) 4
9. Welkos S.L., Vietri N.J., and Gibbs P.H. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog 14 5 (1993) 381-388
10. Welkos S.L. Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb Pathog 10 3 (1991) 183-198
11. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., and Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100 19 (2003) 10925-10930
12. Schneerson R., Kubler-Kielb J., Liu T.Y., et al. Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 100 15 (2003) 8945-8950
13. Joyce J., Cook J., Chabot D., et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 281 8 (2006) 4831-4843
14. Kozel T.R., Murphy W.J., Brandt S., et al. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci USA 101 14 (2004) 5042-5047
15. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., and Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 23 1 (2004) 43-47
16. Mikszta J.A., Sullivan V.J., Dean C., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 2 (2005) 278-288
17. Pitt M.L., Little S.F., Ivins B.E., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
18. Flick-Smith H.C., Eyles J.E., Hebdon R., et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 70 4 (2002) 2022-2028
19. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
20. Verdijk R.M., Mutis T., Esendam B., et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 163 1 (1999) 57-61
21. Schmidt K.N., Leung B., Kwong M., et al. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol 172 1 (2004) 138-143
22. Sivori S., Falco M., Della Chiesa M., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101 27 (2004) 10116-10121
23. Gelman A.E., Zhang J., Choi Y., and Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172 10 (2004) 6065-6073
24. Salem M.L., Kadima A.N., Cole D.J., and Gillanders W.E. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28 3 (2005) 220-228
25. Schulz O., Diebold S.S., Chen M., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 7028 (2005) 887-892
26. Ichinohe T., Watanabe I., Ito S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79 5 (2005) 2910-2919
27. Partidos C.D., Hoebeke J., Moreau E., et al. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol 35 5 (2005) 1521-1529
28. Sloat B.R., and Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res (2006) Epub
29. Perez-Camero G., Congregado F., Bou J.J., and Munoz-Guerra S. Biosynthesis and ultrasonic degradation of bacterial poly(gamma-glutamic acid). Biotechnol Bioeng 63 1 (1999) 110-115
30. Mesnage S., Tosi-Couture E., Gounon P., Mock M., and Fouet A. The capsule and S-layer: two independent and yet compatible macromolecular structures in Bacillus anthracis. J Bacteriol 180 1 (1998) 52-58
31. Makino S., Uchida I., Terakado N., Sasakawa C., and Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 171 2 (1989) 722-730
32. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170 11 (2003) 5636-5643
33. Sloat B.R., and Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 23 2 (2006) 262-269
34. Cui Z., and Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J Control Release 81 1-2 (2002) 173-184
35. Mock M., and Fouet A. Anthrax. Annu Rev Microbiol 55 (2001) 647-671
36. Wang T.T., Fellows P.F., Leighton T.J., and Lucas A.H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol Med Microbiol 40 3 (2004) 231-237
37. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 1-3 (2001) 21-42
38. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 Pt 6 (2001) 1677-1685
39. Welkos S., Friedlander A., Weeks S., Little S., and Mendelson I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 51 10 (2002) 821-831
40. Cui Z., and Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother (2005) 1-13
41. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med Vol.194 (2001) 863-869
42. Ulevitch R.J. Therapeutics targeting the innate immune system. Nat Rev Immunol 4 7 (2004) 512-520
43. Sloat B.R., and Cui Z. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J Pharm Pharmacol 58 4 (2006) 439-447